In addition, the results of Kaplan–Meier survival analysis showed that genetic mutations in p16 represented a decrease in OS (Fig. 5B, P = 8.164E − 4) and DFS (Fig. 5C, P = 0.0130) in sarcoma patients. The gene discussed is CDKN2A; the disease is sarcoma.